封面
市場調查報告書
商品編碼
1136998

日光角化症市場:治療方法,各終端用戶,各地區- 規模,佔有率,展望,機會分析,2022年~2030年

Actinic Keratosis Market, by Treatment (Medication, Surgical Procedure, Photodynamic Therapy, Combination Therapies, By End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 175 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場動態

預計監管機構批准的光化性角化病治療藥物數量的增加將推動預測期內全球光化性角化病市場的增長。

本調查的主要特徵

  • 本報告提供以2021年為基準年的預測期間(2022-2030 年)之全球日光角化症市場的市場規模和復合年增長率(CAGR %)相關的詳細分析。
  • 並闡明不同部門市場的潛在收入機會,說明該市場具有魅力的投資主張矩陣。
  • 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
  • 並基於企業亮點,各類型投資組合、主要焦點、財務業績和市場策略等參數,介紹全球日光角化症市場的主要參與者之企業簡介。
  • 藉由該報告提供的洞察,將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 全球日光角化症市場報告配合該行業的各種利益相關者,包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以透過全球日光角化症市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱的說明

第2章 市場概要

  • 報告內容
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:不同治療
    • 市場明細:各終端用戶
    • 市場明細,各地區
  • 連貫機遇地圖(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 產業趨勢
  • PEST分析
  • 開發平台分析
  • 主要的發展情形
  • 法規情景
  • 流行病學
  • 光化性角化症的治療指南概要

第4章 光化性角化症的全球市場:冠狀病毒(COVID-19)疫情的影響

  • 經濟影響
  • COVID-19流行病學
  • 供給和需求的分析

第5章 光化性角化症的全球市場:不同治療,2017-2030年

  • 藥物療法
  • 外科治療
  • 果酸換膚
  • 冷凍手術
  • 光動力療法
  • 聯合治療
  • 冷凍手術+PDT
  • 冷凍手術+外用治療
  • 局部治療和PD

第6章 光化性角化症的全球市場,各終端用戶,2017年~2030年

  • 醫院和專門診所
  • 居家護理

第7章 光化性角化症的全球市場:各地區,2017年~2030年

  • 北美
  • 美國
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他的南美地區
  • 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他的歐洲地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
  • 中東地區
  • GCC
  • 以色列
  • 其他的中東地區
  • 非洲
  • 南非
  • 中非
  • 北非

第8章 競爭情形

  • 企業簡介
    • Almirall,S.A.
    • Bausch Health Companies Inc.
    • Perrigo Company plc.
    • Sun Pharmaceutical Industries Ltd.
    • Hill Dermaceuticals, Inc.
    • Spear Pharmaceuticals
    • Tolmar Pharmaceuticals, Inc.
    • Biofrontera AG
    • Cipher Pharmaceuticals Inc.
    • Vidac
    • Athenex, Inc.
    • 3M
    • Mayne Pharma Group Limited

第9章 章節

  • 參考文獻
  • 調查手法
簡介目錄
Product Code: CMI1006

Actinic Keratosis (AK) is the most common pre-cancer that forms on skin damaged by chronic exposure to ultraviolet (UV) rays from the sun. Actinic Keratosis is also known as solar keratosis. Actinic keratosis forms like a patch on the skin. The patches usually appear on areas of your body that are often exposed to the sun, such as your face, hands and arms, ears, scalp and legs. Sometimes actinic keratosis can turn into squamous cell skin cancer. For this reason, the lesions are often called pre-cancer. Patches are not life-threatening. But if patches are found and treated early, they do not have the chance to develop into skin cancer. Actinic Keratosis can affect:

  • People with pale skin, blonde or red hair, and blue, green, or gray eyes
  • People with darker skin, hair, and eyes who have been exposed to UV rays without protection
  • Older adults
  • People with suppressed immune systems (due to chemotherapy, AIDS, organ transplant, or other causes)
  • People with rare conditions that make the skin very sensitive to UV rays, such as albinism or xeroderma pigmentosum (XP)

Market Dynamics

Increasing number of drug approvals for the treatment of actinic keratosis from regulatory bodies is expected to drive growth of the global actinic keratosis market during the forecast period. For instance, In November 2017, Perrigo Company plc, an Ireland based healthcare company, had announced that the company had received tentative approval from the U.S. Food and Drug Administration (FDA) for the generic version of Picato Gel (ingenol mebutate) 0.05%. It is indicated for the topical treatment of actinic keratosis.

High incidence rate of skin cancer is expected to drive growth of the global actinic keratosis market. For instance, according to American Academy of Dermatology Association 2022, Skin cancer is the most common cancer in the U.S. It is estimated that approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. It is estimated that the overall incidence of basal cell carcinoma (BCC) increased by 145% between 1976-1984 and between 2000-2010, and the overall incidence of squamous cell carcinoma (SCC) increased 263% over that same period.

Key features of the study:

  • This report provides an in-depth analysis of global actinic keratosis market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global actinic keratosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals Inc., Biofrontera AG., Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, and Mayne Pharma Group Limited.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global actinic keratosis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global actinic keratosis

Detailed Segmentation:

  • Global Actinic Keratosis Market, By Treatment:
    • Medication
    • Surgical Procedure
      • Chemical peel
      • Cryosurgery
      • Curettage and desiccation
      • Laser surgery
    • Photodynamic Therapy
    • Combination Therapies
      • Cryosurgery and PDT
      • Cryosurgery and a topical treatment
      • Topical treatments and PD
  • Global Actinic Keratosis Market, By End User:
    • Hospitals & Specialty Clinics
    • Homecare
  • Global Actinic Keratosis Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Almirall, S.A*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bausch Health Companies Inc.
    • Perrigo Company plc
    • Sun Pharmaceutical Industries Ltd.
    • Hill Dermaceuticals, Inc.
    • Spear Pharmaceuticals
    • Tolmar Pharmaceuticals, Inc.
    • Biofrontera AG
    • Cipher Pharmaceuticals Inc.
    • Vidac
    • Athenex, Inc.
    • 3M
    • Mayne Pharma Group Limited

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Treatment
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Industry Trends
  • PEST Analysis
  • Pipeline Analysis
  • Key Development
  • Regulatory Scenario
  • Epidemiology
  • Overview of Treatment Guidelines for Actinic Keratosis

4. Global Actinic Keratosis Market- Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • COVID-19 Epidemiology
  • Supply and Demand Analysis

5. Global Actinic Keratosis Market, By Treatment, 2017-2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Medication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Surgical Procedure
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Chemical peel
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Cryosurgery
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Photodynamic Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Combination Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Cryosurgery and PDT
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Cryosurgery and a topical treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Topical treatments and PD
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

6. Global Actinic Keratosis Market, By End User, 2017-2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospitals and Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  • Homecare
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

7. Global Actinic Keratosis Market, By Region, 2017 - 2030 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2030
    • Regional Trends
  • North America
    • Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • U.S.
  • Canada
  • Latin America
    • Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Treatment, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By End User, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

8. Competitive Landscape

  • Company Profiles
    • Almirall,S.A.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Bausch Health Companies Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Perrigo Company plc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Hill Dermaceuticals, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Spear Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Tolmar Pharmaceuticals, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Biofrontera AG
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Cipher Pharmaceuticals Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Vidac
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Athenex, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • 3M
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Mayne Pharma Group Limited
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact